These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32081602)

  • 41. TERT promoter mutation analysis as a surrogate to morphology and immunohistochemistry in problematic spindle cell lesions of the urinary bladder.
    Bertz S; Stöhr R; Gaisa NT; Wullich B; Hartmann A; Agaimy A
    Histopathology; 2020 Dec; 77(6):949-962. PubMed ID: 32645760
    [TBL] [Abstract][Full Text] [Related]  

  • 42. hTERT, hTR and TERT promoter mutations as markers for urological cancers detection: A systematic review.
    Morozov A; Potoldykova N; Chinenov D; Enikeev M; Glukhov A; Shpikina A; Goryacheva E; Taratkin M; Malavaud B; Enikeev D
    Urol Oncol; 2021 Aug; 39(8):498.e21-498.e33. PubMed ID: 33676848
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Significance of TERT promoter mutation in differential diagnosis of non-invasive inverted urothelial lesions of bladder].
    Zhang YH; Xie JJ; Wang JG; Wang Y; Zhan XH; Gao J; He HY
    Zhonghua Bing Li Xue Za Zhi; 2023 Dec; 52(12):1216-1222. PubMed ID: 38058037
    [No Abstract]   [Full Text] [Related]  

  • 44. Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis.
    Günes C; Wezel F; Southgate J; Bolenz C
    Nat Rev Urol; 2018 Jun; 15(6):386-393. PubMed ID: 29599449
    [TBL] [Abstract][Full Text] [Related]  

  • 45. TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas.
    Wang K; Liu T; Liu L; Liu J; Liu C; Wang C; Ge N; Ren H; Yan K; Hu S; Björkholm M; Fan Y; Xu D
    Oncotarget; 2014 Apr; 5(7):1829-36. PubMed ID: 24742867
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer.
    Ruan W; Chen X; Huang M; Wang H; Chen J; Liang Z; Zhang J; Yu Y; Chen S; Xu S; Hu T; Li X; Guo Y; Jiang Z; Chen Z; Huang J; Lin T; Fan JB
    Clin Epigenetics; 2021 Apr; 13(1):91. PubMed ID: 33902700
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers.
    Marchese PV; Mollica V; Tassinari E; De Biase D; Giunchi F; Marchetti A; Rosellini M; Fiorentino M; Massari F
    Expert Rev Mol Diagn; 2022 Nov; 22(11):997-1008. PubMed ID: 36503370
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Properties of non-coding mutation hotspots as urinary biomarkers for bladder cancer detection.
    Baxter L; Gordon NS; Ott S; Wang J; Patel P; Goel A; Piechocki K; Silcock L; Sale C; Zeegers MP; Cheng KK; James ND; ; Bryan RT; Ward DG
    Sci Rep; 2023 Jan; 13(1):1060. PubMed ID: 36658180
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Urine TERT promoter mutations-based tumor DNA detection in patients with bladder cancer: A pilot study.
    Jain M; Kamalov D; Tivtikyan A; Balatsky A; Samokhodskaya L; Okhobotov D; Kozlova P; Pisarev E; Zvereva M; Kamalov A
    Mol Clin Oncol; 2021 Dec; 15(6):253. PubMed ID: 34712485
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The role of telomerase activity in non-invasive diagnostics of bladder cancer].
    Glybochko PV; Alyaev JG; Potoldykova NV; Polyakovsky KA; Vinarov AZ; Glukhov AI; Gordeev SA
    Urologiia; 2016 Aug; (4):76-81. PubMed ID: 28247730
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.
    Beukers W; van der Keur KA; Kandimalla R; Vergouwe Y; Steyerberg EW; Boormans JL; Jensen JB; Lorente JA; Real FX; Segersten U; Orntoft TF; Malats N; Malmström PU; Dyrskjot L; Zwarthoff EC
    J Urol; 2017 Jun; 197(6):1410-1418. PubMed ID: 28049011
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.
    Hurst CD; Platt FM; Knowles MA
    Eur Urol; 2014 Feb; 65(2):367-9. PubMed ID: 24035680
    [No Abstract]   [Full Text] [Related]  

  • 53. Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer.
    Leão R; Lee D; Figueiredo A; Hermanns T; Wild P; Komosa M; Lau I; Mistry M; Nunes NM; Price AJ; Zhang C; Lipman T; Poyet C; Valtcheva N; Oehl K; Coelho H; Sayyid R; Gomes AM; Prado E Castro L; Sweet J; Vinagre J; Apolónio J; Stephens D; Faleiro I; Fadaak K; Richard PO; Kulkarni G; Zlotta AR; Hamilton RJ; Castelo-Branco P; Tabori U
    Int J Cancer; 2019 Apr; 144(7):1676-1684. PubMed ID: 30350309
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical evaluation of Bladder CARE, a new epigenetic test for bladder cancer detection in urine samples.
    Piatti P; Chew YC; Suwoto M; Yamada T; Jara B; Jia XY; Guo W; Ghodoussipour S; Daneshmand S; Ahmadi H; Rice J; Bhasin J; Holloway F; Tsai Y; Chihara Y; Liang G
    Clin Epigenetics; 2021 Apr; 13(1):84. PubMed ID: 33882992
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A urinary microRNA (miR) signature for diagnosis of bladder cancer.
    Hofbauer SL; de Martino M; Lucca I; Haitel A; Susani M; Shariat SF; Klatte T
    Urol Oncol; 2018 Dec; 36(12):531.e1-531.e8. PubMed ID: 30322728
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer.
    Liu H; He W; Wang B; Xu K; Han J; Zheng J; Ren J; Shao L; Bo S; Lu S; Lin T; Huang J
    BMC Cancer; 2018 Jun; 18(1):659. PubMed ID: 29907142
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The C228T mutation of TERT promoter frequently occurs in bladder cancer stem cells and contributes to tumorigenesis of bladder cancer.
    Li C; Wu S; Wang H; Bi X; Yang Z; Du Y; He L; Cai Z; Wang J; Fan Z
    Oncotarget; 2015 Aug; 6(23):19542-51. PubMed ID: 26143634
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Urinary Analysis of
    Lotan Y; Raman JD; Konety B; Daneshmand S; Schroeck F; Shariat SF; Black P; de Lange M; Asroff S; Goldfischer E; Efros M; Chong KT; Huang E; Chua HL; Wu QH; Yeow S; Lau W; Yong J; Eng M
    J Urol; 2023 Apr; 209(4):762-772. PubMed ID: 36583640
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Urinary exosomal microRNA-96-5p and microRNA-183-5p expression as potential biomarkers of bladder cancer.
    El-Shal AS; Shalaby SM; Abouhashem SE; Elbary EHA; Azazy S; Rashad NM; Sarhan W
    Mol Biol Rep; 2021 May; 48(5):4361-4371. PubMed ID: 34085193
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Urine cell-based DNA methylation classifier for monitoring bladder cancer.
    van der Heijden AG; Mengual L; Ingelmo-Torres M; Lozano JJ; van Rijt-van de Westerlo CCM; Baixauli M; Geavlete B; Moldoveanud C; Ene C; Dinney CP; Czerniak B; Schalken JA; Kiemeney LALM; Ribal MJ; Witjes JA; Alcaraz A
    Clin Epigenetics; 2018; 10():71. PubMed ID: 29854012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.